vs
Side-by-side financial comparison of Prelude Therapeutics Inc (PRLD) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $5.0M, roughly 1.3× cbdMD, Inc.). cbdMD, Inc. runs the higher net margin — -5.6% vs -303.5%, a 297.8% gap on every dollar of revenue. On growth, Prelude Therapeutics Inc posted the faster year-over-year revenue change (116.7% vs -1.9%).
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
PRLD vs YCBD — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $6.5M | $5.0M |
| Net Profit | $-19.7M | $-283.1K |
| Gross Margin | — | 59.8% |
| Operating Margin | -314.1% | -5.7% |
| Net Margin | -303.5% | -5.6% |
| Revenue YoY | 116.7% | -1.9% |
| Net Profit YoY | 38.9% | -1975.7% |
| EPS (diluted) | $-0.26 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.0M | ||
| Q3 25 | $6.5M | $4.7M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | — | $4.7M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $3.0M | $4.6M | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $4.4M |
| Q4 25 | — | $-283.1K | ||
| Q3 25 | $-19.7M | $-680.0K | ||
| Q2 25 | — | $-895.3K | ||
| Q1 25 | — | $-480.8K | ||
| Q4 24 | — | $15.1K | ||
| Q3 24 | $-32.3M | $-152.8K | ||
| Q2 24 | — | $459.7K | ||
| Q1 24 | — | $-3.0M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 62.3% | ||
| Q4 24 | — | 66.5% | ||
| Q3 24 | — | 53.9% | ||
| Q2 24 | — | 65.8% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | — | -5.7% | ||
| Q3 25 | -314.1% | -14.5% | ||
| Q2 25 | — | -19.6% | ||
| Q1 25 | — | -10.2% | ||
| Q4 24 | — | -1.7% | ||
| Q3 24 | -1145.9% | -6.9% | ||
| Q2 24 | — | -7.4% | ||
| Q1 24 | — | -35.4% |
| Q4 25 | — | -5.6% | ||
| Q3 25 | -303.5% | -14.4% | ||
| Q2 25 | — | -19.4% | ||
| Q1 25 | — | -10.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | -1075.7% | -3.4% | ||
| Q2 24 | — | 8.9% | ||
| Q1 24 | — | -68.8% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.26 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.43 | — | ||
| Q2 24 | — | $-0.15 | ||
| Q1 24 | — | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.0M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.5M | $9.0M |
| Total Assets | $94.8M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.4M | ||
| Q3 25 | $55.0M | $2.3M | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | $1.8M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | $153.6M | $2.5M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.1M |
| Q4 25 | — | $9.0M | ||
| Q3 25 | $58.5M | $7.2M | ||
| Q2 25 | — | $6.1M | ||
| Q1 25 | — | $665.8K | ||
| Q4 24 | — | $1.8M | ||
| Q3 24 | $156.4M | $2.0M | ||
| Q2 24 | — | $3.0M | ||
| Q1 24 | — | $3.1M |
| Q4 25 | — | $11.8M | ||
| Q3 25 | $94.8M | $10.4M | ||
| Q2 25 | — | $9.9M | ||
| Q1 25 | — | $10.9M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | $197.2M | $10.6M | ||
| Q2 24 | — | $13.8M | ||
| Q1 24 | — | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.1M | $-812.5K |
| Free Cash FlowOCF − Capex | — | $-977.3K |
| FCF MarginFCF / Revenue | — | -19.5% |
| Capex IntensityCapex / Revenue | 0.0% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-812.5K | ||
| Q3 25 | $-19.1M | $-240.7K | ||
| Q2 25 | — | $-704.2K | ||
| Q1 25 | — | $-189.5K | ||
| Q4 24 | — | $-317.9K | ||
| Q3 24 | $-27.3M | $167.4K | ||
| Q2 24 | — | $289.8K | ||
| Q1 24 | — | $-704.1K |
| Q4 25 | — | $-977.3K | ||
| Q3 25 | — | $-243.6K | ||
| Q2 25 | — | $-705.7K | ||
| Q1 25 | — | $-205.0K | ||
| Q4 24 | — | $-482.3K | ||
| Q3 24 | $-27.4M | $157.4K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-708.7K |
| Q4 25 | — | -19.5% | ||
| Q3 25 | — | -5.2% | ||
| Q2 25 | — | -15.3% | ||
| Q1 25 | — | -4.3% | ||
| Q4 24 | — | -9.4% | ||
| Q3 24 | -912.0% | 3.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -16.2% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | 2.1% | 0.2% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRLD
Segment breakdown not available.
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
